Discovery and diagnostic value of a novel oncofetal protein: Glypican 3

Advances in Anatomic Pathology

Volumn 21, Issue 6, 2014, Pages 450-460

  Wang, Sean K ^a   Zynger, Debra L ^b   Hes, Ondrej ^d   Yang, Ximing J ^c  

^a STANFORD UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Immunohistochemistry; Oncofetal protein; Testicular cancer; Yolk sac tumor

Indexed keywords

GLYPICAN; GPC3 PROTEIN, HUMAN; TUMOR MARKER;

BIOPSY; BLOOD; CARCINOMA, HEPATOCELLULAR; CHEMISTRY; FEMALE; GENETIC SCREENING; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; OVARIAN NEOPLASMS; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; TESTICULAR NEOPLASMS;

BIOPSY; CARCINOMA, HEPATOCELLULAR; FEMALE; GENETIC TESTING; GLYPICANS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TESTICULAR NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84914166518     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0000000000000043     Document Type: Review

References (95)

1. Filmus J. Glypicans in growth control and cancer. Glycobiology. 2001;11:19R-23R
2. Yayon A, Klagsbrun M, Esko JD, et al. Cell surface, heparanlike molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell. 1991;64:841-848
3. Ho M, Kim H. Glypican-3: a new target for cancer immunotherapy. Eur J Cancer. 2011;47:333-338
4. Li M, Choo B, Wong ZM, et al. Expression of OCI-5/glypican 3 during intestinal morphogenesis: regulation by cell shape in intestinal epithelial cells. Exp Cell Res. 1997;235:3-12
5. Capurro MI, Xiang YY, Lobe C, et al. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res. 2005;65:6245-6254
6. Midorikawa Y, Ishikawa S, Iwanari H, et al. Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer. 2003;103:455-465
7. Song HH, Shi W, Xiang YY, et al. The loss of glypican-3 induces alterations in Wnt signaling. J Biol Chem. 2005;280: 2116-2125
8. Pilia G, Hughes-Benzie RM, MacKenzie A, et al. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet. 1996;12:241-247
9. Cottereau E, Mortemousque I, Moizard MP, et al. Phenotypic spectrum of Simpson-Golabi-Behmel syndrome in a series of 42 cases with a mutation in GPC3 and review of the literature. Am J Med Genet C Semin Med Genet. 2013;163:92-105
10. Hughes-Benzie RM, Hunter AG, Allanson JE, et al. Simpson- Golabi-Behmel syndrome associated with renal dysplasia and embryonal tumor: localization of the gene to Xqcen-q21. Am J Med Genet. 1992;43:428-435
11. Lapunzina P, Badia I, Galoppo C, et al. A patient with Simpson-Golabi-Behmel syndrome and hepatocellular carcinoma. J Med Genet. 1998;35:153-156
12. Cano-Gauci DF, Song HH, Yang H, et al. Glypican-3- deficient mice exhibit developmental overgrowth and some of the abnormalities typical of Simpson-Golabi-Behmel syndrome. J Cell Biol. 1999;146:255-264
13. Kandil DH, Cooper K. Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more. Adv Anat Pathol. 2009;16:125-129
14. Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003;125:89-97
15. Toretsky JA, Zitomersky NL, Eskenazi AE, et al. Glypican-3 expression in Wilms tumor and hepatoblastoma. J Pediatr Hematol Oncol. 2001;23:496-499
16. Yamauchi N,Watanabe A, Hishinuma M, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol. 2005;18:1591-1598
17. Yachnin S, Hsu R, Heinrikson RL, et al. Studies on human alpha-fetoprotein. Isolation and characterization of monomeric and polymeric forms and amino-terminal sequence analysis. Biochim Biophys Acta. 1977;493:418-428
18. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27:1485-1491
19. Hsu HC, Cheng W, Lai PL. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res. 1997;57:5179-5184
20. Filmus J, Capurro M. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma. FEBS J. 2013;280:2471-2476
21. Wang FH, Yip YC, Zhang M, et al. Diagnostic utility of glypican-3 for hepatocellular carcinoma on liver needle biopsy. J Clin Pathol. 2010;63:599-603
22. Wang XY, Degos F, Dubois S, et al. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol. 2006;37:1435-1441
23. Nakatsura T, Yoshitake Y, Senju S, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun. 2003;306:16-25
24. Shirakawa H, Suzuki H, Shimomura M, et al. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci. 2009;100:1403-1407
25. Lai J-P, Oseini AM, Moser CD, et al. The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation. Hepatology. 2010;52:1680-1689
26. Lai J-P, Sandhu DS, Yu C, et al. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology. 2008;47:1211-1222
27. Capurro M, Martin T, Shi W, et al. Glypican-3 binds to frizzled and plays a direct role in the stimulation of canonical Wnt signaling. J Cell Sci. 2014;127:1565-1575
28. Hoti E, Adam R. Liver transplantation for primary and metastatic liver cancers. Transpl Int. 2008;21:1107-1117
29. Wang YX, Liu H. Adult hepatoblastoma: systemic review of the English literature. Dig Surg. 2012;29:323-330
30. Zynger DL, Gupta A, Luan C, et al. Expression of glypican 3 in hepatoblastoma: an immunohistochemical study of 65 cases. Hum Pathol. 2008;39:224-230
31. Chan ES, Pawel BR, Corao DA, et al. Immunohistochemical expression of glypican-3 in pediatric tumors: an analysis of 414 cases. Pediatr Dev Pathol. 2013;16:272-277
32. Levy M, Trivedi A, Zhang J, et al. Expression of glypican-3 in undifferentiated embryonal sarcoma and mesenchymal hamartoma of the liver. Hum Pathol. 2012;43:695-701
33. Zynger DL, Dimov ND, Luan C, et al. Glypican 3: a novel marker in testicular germ cell tumors. Am J Surg Pathol. 2006;30:1570-1575
34. Ulbright TM. Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. Mod Pathol. 2005; 18(suppl 2):S61-S79
35. McKenney JK, Heerema-McKenney A, Rouse RV. Extragonadal germ cell tumors: a review with emphasis on pathologic features, clinical prognostic variables, and differential diagnostic considerations. Adv Anat Pathol. 2007;14:69-92
36. Nogales FF, Preda O, Nicolae A. Yolk sac tumours revisited. A review of their many faces and names. Histopathology. 2012;60:1023-1033
37. Heerema-McKenney A, Harrison MR, Bratton B, et al. Congenital teratoma: a clinicopathologic study of 22 fetal and neonatal tumors. Am J Surg Pathol. 2005;29:29-38
38. Sonneveld DJ, Sleijfer DT, Koops HS, et al. Mature teratoma identified after postchemotherapy surgery in patients with disseminated nonseminomatous testicular germ cell tumors: a plea for an aggressive surgical approach. Cancer. 1998;82:1343-1351
39. Sugimura J, Foster RS, Cummings OW, et al. Gene expression profiling of early- and late-relapse nonseminomatous germ cell tumor and primitive neuroectodermal tumor of the testis. Clin Cancer Res. 2004;10:2368-2378
40. Zynger DL, McCallum JC, Luan C, et al. Glypican 3 has a higher sensitivity than alpha-fetoprotein for testicular and ovarian yolk sac tumour: immunohistochemical investigation with analysis of histological growth patterns. Histopathology. 2010;56:750-757
41. Preda O, Nicolae A, Aneiros-Fernández J, et al. Glypican 3 is a sensitive, but not a specific, marker for the diagnosis of yolk sac tumours. Histopathology. 2011;58:312-314
42. Ota S, Hishinuma M, Yamauchi N, et al. Oncofetal protein glypican-3 in testicular germ-cell tumor. Virchows Arch. 2006;449:308-314
43. Bai S, Wei S, Pasha TL, et al. Immunohistochemical studies of metastatic germ-cell tumors in retroperitoneal dissection specimens: a sensitive and specific panel. Int J Surg Pathol. 2013;21:342-351
44. Bing Z, Pasha T, Tomaszewski JE, et al. CDX2 expression in yolk sac component of testicular germ cell tumors. Int J Surg Pathol. 2009;17:373-377
45. Kao C-S, Idrees MT, Young RH, et al. Solid pattern yolk sac tumor: a morphologic and immunohistochemical study of 52 cases. Am J Surg Pathol. 2012;36:360-367
46. Liu A, Cheng L, Du J, et al. Diagnostic utility of novel stem cell markers SALL4, OCT4, NANOG, SOX2, UTF1, and TCL1 in primary mediastinal germ cell tumors. Am J Surg Pathol. 2010;34:697-706
47. Zynger DL, Everton MJ, Dimov ND, et al. Expression of glypican 3 in ovarian and extragonadal germ cell tumors. Am J Clin Pathol. 2008;130:224-230
48. Ueno T, Tanaka YO, Nagata M, et al. Spectrum of germ cell tumors: from head to toe. Radiographics. 2004;24:387-404
49. Esheba GE, Pate LL, Longacre TA. Oncofetal protein glypican- 3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary. Am J Surg Pathol. 2008;32:600-607
50. Trinh DT, Shibata K, Hirosawa T, et al. Diagnostic utility of CD117, CD133, SALL4, OCT4, TCL1 and glypican-3 in malignant germ cell tumors of the ovary. J Obstet Gynaecol Res. 2012;38:841-848
51. Cao D, Guo S, Allan RW, et al. SALL4 is a novel sensitive and specific marker of ovarian primitive germ cell tumors and is particularly useful in distinguishing yolk sac tumor from clear cell carcinoma. Am J Surg Pathol. 2009;33:894-904
52. Umezu T, Shibata K, Kajiyama H, et al. Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary. J Clin Pathol. 2010;63: 962-966
53. Rabban JT, Zaloudek CJ. A practical approach to immunohistochemical diagnosis of ovarian germ cell tumours and sex cord-stromal tumours. Histopathology. 2013;62:71-88
54. Maeda D, Ota S, Takazawa Y, et al. Glypican-3 expression in clear cell adenocarcinoma of the ovary. Mod Pathol. 2009;22: 824-832
55. Bing Z, Pasha T, Wang L-P, et al. Malignant mixed mullerian tumor: an immunohistochemical study. Pathol Res Int. 2012;2012:569-609
56. Pantanowitz L, Otis CN. Glypican-3 immunohistochemistry in the ovary. Histopathology. 2008;53:115-117
57. Mei K, Liu A, Allan RW, et al. Diagnostic utility of SALL4 in primary germ cell tumors of the central nervous system: a study of 77 cases. Mod Pathol. 2009;22:1628-1636
58. Wang F, Liu A, Peng Y, et al. Diagnostic utility of SALL4 in extragonadal yolk sac tumors: an immunohistochemical study of 59 cases with comparison to placental-like alkaline phosphatase, alpha-fetoprotein, and glypican-3. Am J Surg Pathol. 2009;33:1529-1539
59. Thway K, Selfe J, Missiaglia E, et al. Glypican-3 is expressed in rhabdomyosarcomas but not adult spindle cell and pleomorphic sarcomas. J Clin Pathol. 2011;64:587-591
60. Tretiakova M, Zynger DL, Dimov ND, et al. Glypican 3 protein expression in Wilms tumors. Mod Pathol. 2006;19: 300A
61. Ou-Yang RJ, Hui P, Yang XJ, et al. Expression of glypican 3 in placental site trophoblastic tumor. Diagn Pathol. 2010;5:64
62. Ushiku T, Uozaki H, Shinozaki A, et al. Glypican 3-expressing gastric carcinoma: distinct subgroup unifying hepatoid, clearcell, and α-fetoprotein-producing gastric carcinomas. Cancer Sci. 2009;100:626-632
63. Ushiku T, Shinozaki A, Shibahara J, et al. SALL4 represents fetal gut differentiation of gastric cancer, and is diagnostically useful in distinguishing hepatoid gastric carcinoma from hepatocellular carcinoma. Am J Surg Pathol. 2010;34:533-540
64. Ikeda H, Sato Y, Yoneda N, et al. α-Fetoprotein-producing gastric carcinoma and combined hepatocellular and cholangiocarcinoma show similar morphology but different histogenesis with respect to SALL4 expression. Hum Pathol. 2012;43:1955-1963
65. Mounajjed T, Zhang L, Wu T-T. Glypican-3 expression in gastrointestinal and pancreatic epithelial neoplasms. Hum Pathol. 2013;44:542-550
66. Kai K, Nakamura J, Ide T, et al. Hepatoid carcinoma of the pancreas penetrating into the gastric cavity: a case report and literature review. Pathol Int. 2012;62:485-490
67. Aviel-Ronen S, Lau SK, Pintilie M, et al. Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma. Mod Pathol. 2008;21:817-825
68. Gailey MP, Bellizzi AM. Immunohistochemistry for the novel markers glypican 3, PAX8, and p40 (ΔNp63) in squamous cell and urothelial carcinoma. Am J Clin Pathol. 2013;140:872-880
69. Lin Q, Xiong L-W, Pan X-F, et al. Expression of GPC3 protein and its significance in lung squamous cell carcinoma. Med Oncol. 2012;29:663-669
70. Nakatsura T, Nishimura Y. Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma. BioDrugs. 2005;19:71-77
71. Kandil D, Leiman G, Allegretta M, et al. Glypican-3 protein expression in primary and metastatic melanoma: a combined immunohistochemistry and immunocytochemistry study. Cancer. 2009;117:271-278
72. Okoń K. Glypican-3 is expressed in chromophobe renal cell carcinomas. Pol J Pathol. 2008;59:15-20
73. Zhang L, Liu H, Sun L, et al. Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray- based study. Acta Histochem. 2012;114:547-552
74. Zynger DL, Dimov ND, Eisengart LJ. GPC3 immunohistochemical expression in fetal and adult tissues. Mod Pathol. 2007;20(suppl):A1451
75. Powell CA, Xu G, Filmus J, et al. Oligonucleotide microarray analysis of lung adenocarcinoma in smokers and nonsmokers identifies GPC3 as a potential lung tumor suppressor. Chest. 2002;121:6S-7S
76. Zhu Z, Friess H, Kleeff J, et al. Glypican-3 expression is markedly decreased in human gastric cancer but not in esophageal cancer. Am J Surg. 2002;184:78-83
77. Kim H, Xu G-L, Borczuk AC, et al. The heparan sulfate proteoglycan GPC3 is a potential lung tumor suppressor. Am J Respir Cell Mol Biol. 2003;29:694-701
78. Capurro MI, Xu P, Shi W, et al. Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. Dev Cell. 2008;14:700-711
79. Iglesias BV, Centeno G, Pascuccelli H, et al. Expression pattern of glypican-3 (GPC3) during human embryonic and fetal development. Histol Histopathol. 2008;23: 1333-1340
80. Khan S, Blackburn M, Mao DL, et al. Glypican-3 (GPC3) expression in human placenta: localization to the differentiated syncytiotrophoblast. Histol Histopathol. 2001;16:71-78
81. Ogawa M, Yanoma S, Nagashima Y, et al. Paradoxical discrepancy between the serum level and the placental intensity of PP5/TFPI-2 in preeclampsia and/or intrauterine growth restriction: possible interaction and correlation with glypican-3 hold the key. Placenta. 2007;28:224-232
82. McKnight R, Nassar A, Cohen C, et al. Arginase-1: a novel immunohistochemical marker of hepatocellular differentiation in fine needle aspiration cytology. Cancer Cytopathol. 2012; 120:223-229
83. Wang F, Jing X, Wang T, et al. Differential diagnostic value of GPC3-CD34 combined staining in small liver nodules with diameter less than 3 cm. Am J Clin Pathol. 2012;137: 937-945
84. Jin G-Z, Dong H, Yu W-L, et al. A novel panel of biomarkers in distinction of small well-differentiated HCC from dysplastic nodules and outcome values. BMC Cancer. 2013;13:161
85. Filmus J, Capurro M. Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diagn. 2004;8:207-212
86. Chen M, Li G, Yan J, et al. Reevaluation of glypican-3 as a serological marker for hepatocellular carcinoma. Clin Chim Acta Int J Clin Chem. 2013;423:105-111
87. Ishiguro T, Sugimoto M, Kinoshita Y, et al. Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res. 2008;68:9832-9838
88. Nakano K, Orita T, Nezu J, et al. Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2009;378:279-284
89. Zhu AX, Gold PJ, El-Khoueiry AB, et al. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2013;19:920-928
90. Feng M, Gao W, Wang R, et al. Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc Natl Acad Sci USA. 2013;110:E1083-E1091
91. Nobuoka D, Yoshikawa T, Sawada Y, et al. Peptide vaccines for hepatocellular carcinoma. Hum Vaccin Immunother. 2013;9: 210-212
92. Purcell R, Childs M, Maibach R, et al. Potential biomarkers for hepatoblastoma: results from the SIOPEL-3 study. Eur J Cancer. 2012;48:1853-1859
93. Fukuzawa H, Urushihara N, Fukumoto K, et al. Can we predict the prognosis of resectable hepatoblastoma from serum alpha-fetoprotein response during preoperative chemotherapy? Pediatr Surg Int. 2012;28:887-891
94. Anatelli F, Chuang S-T, Yang XJ, et al. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy. Am J Clin Pathol. 2008;130: 219-223
95. Wang HL, Anatelli F, Zhai QJ, et al. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions. Arch Pathol Lab Med. 2008;132:1723-1728.